JP4718778B2 - ウエストナイルワクチン - Google Patents

ウエストナイルワクチン Download PDF

Info

Publication number
JP4718778B2
JP4718778B2 JP2003561501A JP2003561501A JP4718778B2 JP 4718778 B2 JP4718778 B2 JP 4718778B2 JP 2003561501 A JP2003561501 A JP 2003561501A JP 2003561501 A JP2003561501 A JP 2003561501A JP 4718778 B2 JP4718778 B2 JP 4718778B2
Authority
JP
Japan
Prior art keywords
composition
west nile
virus
vaccine
nile virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003561501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515236A (ja
JP2005515236A5 (OSRAM
Inventor
シェン−ジュエ・チュ
Original Assignee
ワイス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワイス・エルエルシー filed Critical ワイス・エルエルシー
Publication of JP2005515236A publication Critical patent/JP2005515236A/ja
Publication of JP2005515236A5 publication Critical patent/JP2005515236A5/ja
Application granted granted Critical
Publication of JP4718778B2 publication Critical patent/JP4718778B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2003561501A 2001-07-27 2002-07-23 ウエストナイルワクチン Expired - Lifetime JP4718778B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
US60/308,334 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010255105A Division JP2011057692A (ja) 2001-07-27 2010-11-15 ウエストナイルワクチン

Publications (3)

Publication Number Publication Date
JP2005515236A JP2005515236A (ja) 2005-05-26
JP2005515236A5 JP2005515236A5 (OSRAM) 2009-04-09
JP4718778B2 true JP4718778B2 (ja) 2011-07-06

Family

ID=27613166

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003561501A Expired - Lifetime JP4718778B2 (ja) 2001-07-27 2002-07-23 ウエストナイルワクチン
JP2010255105A Pending JP2011057692A (ja) 2001-07-27 2010-11-15 ウエストナイルワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010255105A Pending JP2011057692A (ja) 2001-07-27 2010-11-15 ウエストナイルワクチン

Country Status (24)

Country Link
US (8) US7153513B2 (OSRAM)
EP (3) EP2283858A3 (OSRAM)
JP (2) JP4718778B2 (OSRAM)
KR (2) KR20040028952A (OSRAM)
CN (2) CN1273189C (OSRAM)
AU (1) AU2002365244B2 (OSRAM)
BE (1) BE2014C006I2 (OSRAM)
BR (1) BRPI0211492B1 (OSRAM)
CA (1) CA2452545C (OSRAM)
CY (1) CY2014010I2 (OSRAM)
DK (1) DK1427444T3 (OSRAM)
ES (1) ES2435095T3 (OSRAM)
FR (1) FR14C0016I2 (OSRAM)
HR (1) HRP20040195B1 (OSRAM)
HU (2) HU228690B1 (OSRAM)
LU (1) LU92348I2 (OSRAM)
ME (1) ME00491B (OSRAM)
MX (1) MXPA04000680A (OSRAM)
NZ (3) NZ531265A (OSRAM)
PL (2) PL212212B1 (OSRAM)
PT (1) PT1427444E (OSRAM)
RS (1) RS53184B (OSRAM)
WO (1) WO2003061555A2 (OSRAM)
ZA (1) ZA200401596B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
PL212212B1 (pl) * 2001-07-27 2012-08-31 Wyeth Corp Kompozycja szczepionki przeciwko zakażeniu wirusem Zachodniego Nilu, kompozycja końskiej szczepionki, szczepionka wirusa Zachodniego Nilu oraz zastosowania
WO2005024427A2 (en) * 2003-09-09 2005-03-17 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
AU2006232865A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of WNV DNA vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
US8048429B2 (en) * 2005-06-24 2011-11-01 Intervet International B.V. Inactivated chimeric flavivirus
BRPI0617735B1 (pt) * 2005-10-19 2022-05-17 University Of Florida Research Foundation Inc Composições compreendendo vírus isolados, polinucleotídeos, ou polipeptídeos, construções de expressão, vacinas, kits para proteger um canino da infecção do vírus influenza, uso do vírus na preparação de composição farmacêutica bem como método in vitro para detecção de um vírus influenza que é capaz de infectar um animal canídeo
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
AU2006338210A1 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
EA018030B1 (ru) 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
ME01000B (me) 2007-11-06 2012-10-20 Zoetis Services Llc Živa vakcina avirulentne mycoplasma hyopneumoniae sa adjuvansom
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
CA2732035A1 (en) * 2008-07-30 2010-02-04 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
BRPI0918897B1 (pt) * 2008-08-29 2021-06-15 Boehringer Ingelheim Animal Health USA Inc. Composição imunogênica e seus usos
WO2011043962A2 (en) * 2009-10-07 2011-04-14 Wyeth Llc Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof
MX350718B (es) 2011-03-14 2017-09-14 Boehringer Ingelheim Vetmedica Inc Vacuna de rinitis equina.
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
LT3542819T (lt) * 2013-05-14 2021-11-10 Zoetis Services Llc Naujos vakcinos kompozicijos, apimančios imunostimuliuojančius oligonukleotidus
CN109078179A (zh) * 2013-09-05 2018-12-25 硕腾服务有限责任公司 Hendra和Nipah病毒G糖蛋白免疫原性组合物
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
CN113905759A (zh) 2019-02-27 2022-01-07 罗切斯特大学 用于预防和控制马的马流感病毒(eiv)的多价减毒活流感疫苗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
SI0968722T1 (sl) * 1994-05-10 2007-10-31 Wyeth Corp Izboljĺ ano, modificirano ĺ˝ivo cepivo proti brsv
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU778988B2 (en) 1998-06-04 2004-12-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleic acid vaccines for prevention of flavivirus infection
CA2424216A1 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
AU2002305028A1 (en) 2001-02-28 2002-10-28 Brown University Research Foundation West nile virus epitopes and uses thereof
AU2002309508A1 (en) * 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
PL212212B1 (pl) * 2001-07-27 2012-08-31 Wyeth Corp Kompozycja szczepionki przeciwko zakażeniu wirusem Zachodniego Nilu, kompozycja końskiej szczepionki, szczepionka wirusa Zachodniego Nilu oraz zastosowania
AU2003263853A1 (en) 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Also Published As

Publication number Publication date
WO2003061555A2 (en) 2003-07-31
YU8004A (sh) 2006-08-17
HU228690B1 (en) 2013-05-28
CA2452545A1 (en) 2003-07-31
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
PL212212B1 (pl) 2012-08-31
BE2014C006I2 (OSRAM) 2021-02-04
EP2281572A1 (en) 2011-02-09
JP2005515236A (ja) 2005-05-26
KR20040028952A (ko) 2004-04-03
KR20090053967A (ko) 2009-05-28
US20070231349A1 (en) 2007-10-04
EP2283858A2 (en) 2011-02-16
NZ553165A (en) 2008-09-26
ME00491B (me) 2011-10-10
US7648705B2 (en) 2010-01-19
US20070166326A1 (en) 2007-07-19
PT1427444E (pt) 2013-11-19
PL368535A1 (en) 2005-04-04
PL220846B1 (pl) 2016-01-29
US20070231350A1 (en) 2007-10-04
CY2014010I2 (el) 2024-02-16
HUP0401606A3 (en) 2005-02-28
WO2003061555A3 (en) 2004-04-15
CN1535157A (zh) 2004-10-06
ES2435095T3 (es) 2013-12-18
RS53184B (sr) 2014-06-30
ZA200401596B (en) 2005-07-27
US7153513B2 (en) 2006-12-26
US20070166802A1 (en) 2007-07-19
NZ570270A (en) 2010-08-27
BRPI0211492B1 (pt) 2016-06-21
US20070178119A1 (en) 2007-08-02
DK1427444T3 (da) 2013-11-04
HUP0401606A2 (hu) 2004-11-29
US20030091595A1 (en) 2003-05-15
FR14C0016I1 (OSRAM) 2014-03-28
US7445787B2 (en) 2008-11-04
CN1935258A (zh) 2007-03-28
PL398575A1 (pl) 2012-06-18
JP2011057692A (ja) 2011-03-24
FR14C0016I2 (fr) 2015-07-24
US20070166325A1 (en) 2007-07-19
HUS1300055I1 (hu) 2016-08-29
NZ531265A (en) 2008-08-29
LU92348I9 (OSRAM) 2019-01-02
CY2014010I1 (el) 2020-05-29
AU2002365244B2 (en) 2007-12-06
BR0211492A (pt) 2004-08-17
US7648706B2 (en) 2010-01-19
CN1273189C (zh) 2006-09-06
CA2452545C (en) 2015-06-09
HK1066470A1 (en) 2005-03-24
HRP20040195B1 (hr) 2014-07-18
US20070166324A1 (en) 2007-07-19
MXPA04000680A (es) 2004-04-05
EP2283858A3 (en) 2011-03-23
EP1427444A4 (en) 2008-01-02
LU92348I2 (fr) 2014-09-22
HRP20040195A2 (en) 2004-08-31
CN1935258B (zh) 2013-04-03

Similar Documents

Publication Publication Date Title
JP4718778B2 (ja) ウエストナイルワクチン
AU2002365244A1 (en) West nile vaccine
US6551598B2 (en) Vaccination against canine herpesvirosis and vaccines therefor
AU782657B2 (en) Vaccination against canine herpesvirus infection and vaccines
HK1066470B (en) West nile vaccine
BR122015019697B1 (pt) composição de vacina para west nile, e uso de plasmídeo com inserções de sequência de dna de vírus west nile na preparação da mesma

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090127

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090707

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090807

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101115

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110315

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110401

R150 Certificate of patent or registration of utility model

Ref document number: 4718778

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D03

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term